SGLT2 inhibitor lowers risk of kidney failure in type 2 diabetes
Patients with type 2 diabetes mellitus and chronic kidney disease have a lower risk of kidney failure and cardiovascular events if they are treated with canagliflozin, research has confirmed.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Heart | Invokana | SGLT2 Inhibitors | Urology & Nephrology